C4 Therapeutics Stock (NASDAQ:CCCC), Trade Ideas

C4 Therapeutics

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

BITF

CCCC

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

NNOX

SSRM

TVGN

U.S. stock futures were lower this morning, with the Dow futures trading lower by around 50 points on Tuesday.

Capital One Financial To Acquire Discover, Joins SSR Mining And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

C4 Therapeutics, Inc. (NASDAQ: CCCC) shares are trading higher Friday, and the stock has gained more than 350% over the past five days.

What&#39;s Going On With C4 Therapeutics Stock?

Stock_Whisper_Index_Logo_6-copy

Exclusives

AMZN

FRGT

INHD

STTK

TPIC

A look at five stocks that saw increased interest from Benzinga readers during the week.

Benzinga&#39;s &#39;Stock Whisper&#39; Index: 5 Stocks Investors Secretly Monitor But Don&#39;t Talk About Yet

C4 Therapeutics Inc

C4 Therapeutics (CCCC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Etzer Darout fro...

Strong Financials and Promising Drug Pipeline Bolster Buy Rating for C4 Therapeutics

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on C4 Therapeutics (CCCC – Research Report), Insulet (P...

Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Insulet (PODD) and Healthequity (HQY)

C4 Therapeutics Inc (CCCC) has fallen Friday morning, with the stock declining -0.57% in pre-market trading to 8.75. CCCC's short-term technical score of 72 indicates that the stock has traded more bullishly over the last month than 72% of stocks on the market. In the Biotechnology industry, which ranks 103 out of 146 indu

C4 Therapeutics Inc (CCCC) is down 0.57% Friday In Premarket Trading

Analysts have been eager to weigh in on the Healthcare sector with new ratings on C4 Therapeutics (CCCC – Research Report), Halozyme (HALO – Resear...

Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Halozyme (HALO) and Eli Lilly & Co (LLY)

C4 Therapeutics Inc (CCCC) stock has risen 51.72% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. C4 Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CCCC!See Full CCCC ReportWhat is Stock Sentiment?Sentiment is a

Should You Buy C4 Therapeutics Inc (CCCC) Stock After it Is Up 51.72% in a Week?

C4 Therapeutics Inc (CCCC) has gained Thursday morning, with the stock gaining 4.38% in pre-market trading to 11.43. CCCC's short-term technical score of 85 indicates that the stock has traded more bullishly over the last month than 85% of stocks on the market. In the Biotechnology industry, which ranks 95 out of 146 indus

Should You Sell C4 Therapeutics Inc (CCCC) Stock Thursday Morning?

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

The latest announcement is out from C4 Therapeutics (CCCC). C4 Therapeutics, Inc. has partnered with Merck KGaA in a significant deal to advance ca...

C4 Therapeutics Strikes Major Oncology Deal with Merck KGaA

C4 Therapeutics (CCCC) has shared an update. C4 Therapeutics, Inc. has initiated a strategic repricing of stock options to incentivize and retain k...

C4 Therapeutics Initiates Stock Option Repricing for Retention

C4 Therapeutics Inc (CCCC) is around the top of the Biotechnology industry according to InvestorsObserver. CCCC received an overall rating of 76, which means that it scores higher than 76 percent of all stocks. C4 Therapeutics Inc also achieved a score of 91 in the Biotechnology industry, putting it above 91 percent of Bio

C4 Therapeutics Inc (CCCC) has fallen -18.87% in a Week, Should You Hold?

HALO

PODD

Press Releases

General

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Opinion

Thinking about buying stock in Estrella Immunopharma, Novo Nordisk, C4 Therapeutics, Plug Power, or LQR House?

Thinking about buying stock in Ibio Inc, Nokia, C4 Therapeutics, 1847 Holdings, or CleanSpark?

Thinking about buying stock in Alibaba Group, Akebia Therapeutics, Plug Power, AMC Entertainment, or C4 Therapeutics?

Thinking about buying stock in C4 Therapeutics, Safety Shot, Intuitive Machines, Cardiol Therapeutics, or Iovance Biotherapeutics?

Earnings

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Health Care

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024